Immunodermatology News

The Hidradenitis Suppurativa Symptom Diary, which was developed as a patient-reported outcome measurement, demonstrated content validity, according to a poster presented at AAD VMX 2021.

Janus kinase inhibitors “may prove useful” in a wider range of immune-mediated inflammatory diseases, including refractory cutaneous dermatomyositis, chronic plaque psoriasis and other conditions, according to a speaker here.

Among patients with various malignancies, treatment with combination immune checkpoint inhibitor therapy was associated with increased incidence of cutaneous events compared with checkpoint monotherapy, according to a study.

Patients with hidradenitis suppurativa who were treated with the biosimilar infliximab-abda experienced similar improvement in their condition as those who received infliximab, according to a study.

Pediatric morphea lesions are not distributed randomly, and the location on the body can help clinicians understand extracutaneous manifestation risk factors, according to a study.

Pediatric patients with hidradenitis suppurativa experienced delays in both diagnosis and treatment initiation, according to a study.

Black patients who presented with cutaneous sarcoidosis had an increased risk for systemic disease and cardiovascular involvement compared with other racial groups, according to findings presented at Maui Derm for Dermatologists.

A study regarding COVID-19’s impact on individuals with immune-mediated diseases such as hidradenitis suppurativa and psoriasis was the most-read immunodermatology article on Healio/Dermatology in 2020.

Women were more likely than men to experience a number of adverse sexual health outcomes associated with hidradenitis suppurativa, according to a systematic review.

Patients with systemic autoimmune rheumatic diseases and COVID-19 may be at greater risk for hospitalization, ICU admission, acute renal failure and venous thromboembolism, according to data published in Arthritis & Rheumatology.